ReGen reported results for 2006 that were slightly ahead of our expectations, the highlight being a near four-fold increase in revenues. However, its investment proposition centres on its two key scientific programmes, Colostrinin and zolpidem, both of which should reach important milestones this year.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here